Donovan Joanne M.'s Form 4/A amendment
AmendedEdgewise Therapeutics, Inc. (EWTX) · filed Aug 17, 2026
- Accession no.
- 0001644087-26-000006
- Filed
- Aug 17, 2026, 6:41 PM ET
- Trade date
- Aug 12, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Aug 14, 2026
This filing lists 1 derivative transaction. It carries over 10 transactions from the original filing that it did not restate. Open-market sales total $412.7K. It was filed 5 days after the trade.
This amendment restates part of 0001644087-26-000005 (filed Aug 14, 2026). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Donovan Joanne M.CIK 0001644087 | Officer (CMO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | AGrant or awardAcquired | +65,000 | $0.00 | $0 | 65,000 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001644087-26-000005 (filed Aug 14, 2026).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | MOption exerciseAcquired | +5,781 | $0.00 | $0 | 11,035 | Direct | |
| Aug 12, 2026 | Common Stock | MOption exerciseAcquired | +7,031 | $0.00 | $0 | 18,066 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −2,839 | $43.78F3 | −$124,302.78 | 15,227 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −2,779 | $43.71F4 | −$121,462.59 | 12,448 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −104 | $44.43F5 | −$4,620.23 | 12,344 | Direct | |
| Aug 12, 2026 | Common Stock | SSaleDisposed | −800 | $44.52F6 | −$35,614 | 11,544 | Direct | |
| Aug 13, 2026 | Common Stock | SSaleDisposed | −2,919 | $43.41F8 | −$126,703.57 | 8,625 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | MOption exerciseDisposed | −5,781 | $0.00 | $0 | 11,563 | Direct | |
| Aug 12, 2026 | Common Stock | MOption exerciseDisposed | −7,031 | $0.00 | $0 | 21,094 | Direct | |
| Aug 12, 2026 | Common Stock | AGrant or awardAcquired | +32,500 | $0.00 | $0 | 32,500 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F3
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Remarks
This amendment corrects the exercise price of the reported option grant, which was reported as $0.00 due to a clerical/administrative error. The correct exercise price is $43.56, which reflects the fair market value of the underlying security on the date of grant.